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Abstract  The  antiviral  treatment  of  Hepatitis  C  virus  (HCV)  infection  is  changing  rapidly.  Pegin-
terferon  and  ribavirin  are  no  longer  the  standard  of  care  therapy  and  are  being  replaced  by  new
drugs with  greater  efﬁcacy  and  fewer  adverse  effects.  These  new  direct-acting  antivirals  (DAAs),
incorporated  in  interferon-based  or  all-oral  regimens,  cure  more  than  90%  of  infections,  even
in patients  before  considered  difﬁcult  to  treat,  such  as  cirrhotic  and  non-responders.  These
agents allow  shortening  the  treatment  duration,  improving  sustained  response  rates  (SVR)  and
have reduced  toxicity.  The  goal  of  this  review  is  to  discuss  the  current  stage  of  HCV  therapy.
We describe  the  mechanisms  of  the  new  drugs,  the  efﬁcacy  of  the  therapeutic  regimens,  and
the predictors  of  SVR.  Individual  approach  should  be  based  on  the  different  combinations  of
drugs, and  treatment  strategy  should  take  into  account  the  proﬁle  of  the  patient,  the  efﬁcacy
and safety  of  drugs  as  well  as  the  reimbursement  policy.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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Guia  Prático  para  a  Terapêutica  Antivírica  da  Hepatite  C  Crónica
Resumo  A  terapêutica  antivírica  da  infecc¸ão  pelo  vírus  da  Hepatite  C  (VHC)  está  em  aceleradaTerapêutica  tripla;
Antivirais  de  acc¸ão
directa,  regimes  sem
interferão
transformac¸ão. A  combinac¸ão  de  peginterferão  e  ribavirina,  até  aqui  a  regra  do  tratamento,  está
em vias  de  ser  substituída  por  fármacos  mais  eﬁcazes  e  melhor  tolerados.  Estes  novos  antivíricos
de acc¸ão  directa  (AADs),  incorporados  em  esquemas  terapêuticos  com  ou  sem  interferão,  curam
a infecc¸ão  em  mais  de  90%  dos  casos,  mesmo  em  doentes  antes  considerados  como  difíceis  de
tratar, como  são  os  cirróticos  e  os  não  responsivos.  Os  AADs  permitem  encurtar  a  durac¸ão  do
tratamento,  melhorar  a  resposta  virológica  mantida  (RVM),  e  são  praticamente  isentos  de
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toxicidade.  Com  esta  revisão  pretendemos  discutir  o  estado  actual  da  terapêutica  da  hepatite
C, descrevendo  o  mecanismo  de  acc¸ão  dos  novos  fármacos,  a  eﬁcácia  dos  diversos  regimes
terapêuticos,  e  os  factores  predizentes  de  resposta.  A  escolha  do  regime  terapêutico  dependerá
das combinac¸ões  disponíveis,  devendo  a  estratégia  de  tratamento  ter  em  conta  o  perﬁl  clínico
do doente,  a  eﬁcácia  e  a  seguranc¸a  dos  fármacos,  bem  como  da  política  de  reembolso  adoptada.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos
os direitos  reservados.
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that  half  of  the  patients  with  the  most  prevalent  genotype. Introduction
epatitis  C  virus  (HCV)  affects  2.3--2.8%  of  the  world
opulation.1,2 It  is  a  major  cause  of  chronic  hepatitis,  cir-
hosis  and  hepatocellular  carcinoma  (HCC)  and  the  main
ndication  for  liver  transplantation.3 It  carries  a  heavy
urden  with  a  signiﬁcant  increase  in  the  incidence  of  cir-
hosis  and  HCC  expected  over  the  next  few  years.4,5
Over  the  last  thirty  years  outstanding  advances  were
chieved  in  the  management  of  chronic  Hepatitis  C,  ﬁrst
ith  a  peginterferon  and  ribavirin  combination  and  more
ecently  with  the  protease  inhibitor-based  triple  ther-
py  with  boceprevir  and  telaprevir.  Sustained  virological
esponse  (SVR)  rate,  the  clinical  deﬁnition  of  disease  cure,  is
bove  70%  in  the  patients  with  genotype  1  treated  with  ﬁrst-
eneration  protease-inhibitors.6,7 Viral  eradication  achieved
ith  antiviral  therapy  results  in  relevant  health  gains,
ainly  in  patients  with  cirrhosis,  reducing  hepatic  decom-
ensation,  HCC  and  risk  of  death.8,9
Sofosbuvir,10,11 a  pangenotypic  HCV  polymerase  inhibitor,
n  combination  with  peginterferon  and  ribavirin  or  as  an
ll-oral  regimen  associated  either  to  ledipasvir12 or  to
aclatasvir13 --  both  NS5A  replication  complex  inhibitors  --
ncreases  the  SVR  rate  to  more  than  90%  in  all  genotypes.
ifﬁcult-to-treat  patients,  such  as  patients  with  cirrhosis
nd  non-responders  to  double  or  even  triple  therapy  with
rotease-inhibitors  obtain  similar  SVR  rates  as  non-treated
atients.12 New  direct-acting  antiviral  drugs,  interferon-
ree,  are  coming  on  to  the  market,  improving  the  revolution
n  Hepatitis  C  management.  Therapeutic  regimens  with
hose  drugs  will  be  more  comfortable,  shorter  and  more
fﬁcient,  generally  free  from  adverse  effects  and  drug  inter-
ctions.  In  addition  and  just  as  important,  this  will  allow  for
reatment  of  previously  excluded  patients  such  as  those  with
ecompensated  cirrhosis,  transplant  recipients  and  all  the
emaining  patients  ineligible  for  interferon  therapy.
Despite  progress  to  better  tolerated  therapies,  and  mul-
iple  possible  combinations,  the  choice  of  the  most  suitable
egimen  regarding  genotype  are  yet  to  be  clearly  deﬁned.
n  the  present  study  we  carried  out  a  review  of  the  efﬁ-
acy  of  the  different  management  alternatives,  opening  a
indow  towards  the  near  future.  We  recommend  a  manage-
ent  strategy  for  chronic  Hepatitis  C,  focused  on  the  patient
nd  in  the  context  of  scarce  access  to  direct-acting  antiviral
rugs  (DAAs).
. Double therapy with peginterferon and
ibavirin
eginterferon  alfa  and  ribavirin  combination,  known  as  dou-
le  therapy,  has  been  the  standard  in  chronic  Hepatitis  C
i
S
tanagement  over  the  last  twelve  years.  This  regimen  yields
ariable  results,  according  to  genotype,  basal  viraemia,
tage  of  liver  ﬁbrosis  and  viral  kinetics  during  treatment.14
.1.  Therapeutic  regimen
ndependently  of  viral  genotype,  peginterferon  alfa-2a
PegIFN-2a)  or  peginterferon  alfa-2b  (PegIFN-2b)  dosage
hould  be  180  g/week  and  1.5  g/kg  body  weight/week,
espectively.  Ribavirin  (RBV)  dosage  depends  on  genotype:
5  mg/kg  body  weight  (1200  or  1000  mg/day,  depending  on
atient’s  body  weight  above  or  below  75  kg,  with  PegIFN-2a,
r  800--1400  mg/day,  according  to  body  weight,  with  PegIFN-
b)  in  patients  with  genotypes  1,  4,  5  and  6.  In  patients  with
enotypes  2  and  3,  the  dosage  is  800  mg  (administered  as
00  mg  b.i.d.).
Treatment  duration  is  48  weeks  in  patients  with  geno-
ypes  1,  4,  5 and  6,  and  24  weeks  with  genotypes  2  and  3.
reatment  may  be  extended  to  72  weeks  in  patients  with
enotypes  1  and  4  when  a  delayed  viral  response  occurs
nd  up  to  48  weeks  in  patients  with  genotypes  2  and  3
n  the  absence  of  rapid  virological  response  (RVR),  as  long
s  an  HCV  RNA  reduction  >  2  log10 occurs  by  week  12  of
reatment.14 In  any  event,  therapy  should  be  discontinued
t  week  24  when  HCV  RNA  is  still  detectable.
Alternatively,  patients  should  undergo  a shorter  duration
f  therapy  under  certain  conditions:  24  weeks  in  patients
ith  genotype  1  with  basal  viraemia  <  400,000  IU/mL  and
VR,  i.e.  with  undetectable  HCV  RNA  at  week  4;  16  weeks
n  non-cirrhotic,  low  basal  viraemia  and  RVR  patients  with
enotype  2  or  3.14
In  order  to  avoid  futile  treatment,  therapy  should  be  dis-
ontinued,  independently  of  viral  genotype,  in  the  presence
f  an  HCV  RNA  reduction  <  2  log10 at  week  12  or  if  HCV  RNA
s  still  detectable  at  week  24.
.2.  Efﬁcacy
VR  in  non-treated  patients  varies  between  42%  and  46%
n  patients  with  genotype  1  and  between  76%  and  84%  in
atients  with  genotype  2  and  3.15--17 In  clinical  practice,
he  efﬁcacy  of  chronic  Hepatitis  C  management  with  dou-
le  therapy  is  around  50%.18 In  Europe,  the  percentage  of
atients  (approximately  50%)  with  genotype  1  with  a  positive
esponse  to  therapy  is  higher  than  in  the  US,  which  meansn  the  Western  countries  are  not  cured.  This  variability  in
VR  is  related  to  the  patient’s  characteristics,  compliance
o  treatment  and  medical  expertise.
(
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The  response  to  retreatment  is  difﬁcult  to  determine  due
to  study  heterogeneity,  related  to  patient’s  characteristics,
the  stage  of  the  disease  and  mainly  to  the  previous  thera-
peutic  regimen.  In  general,  it  is  accepted  that  SVR  rate  with
PegIFN/RBV  retreatment  is  very  low.  HALT-C19 and  EPIC20
studies,  involving  a  high  number  of  patients,  the  former
including  exclusively  patients  with  advanced  ﬁbrosis,  found
a  global  SVR  of  18%  and  22%,  respectively.  Nevertheless,  in
relapsers  after  PegIFN/RBV  therapy,  a  23%  SVR  was  obtained
with  genotype  1  and  57%  with  genotype  2/3;  in  addition,  4%
SVR  and  36%  SVR  were  obtained  in  non-responders,  respec-
tively.  The  stage  of  ﬁbrosis  also  affects  the  response  rate:
SVR  in  patients  with  F2  and  F4  was  16%  and  9%  with  genotype
1  and  55%  and  45%  with  genotype  2/3,  respectively.20
Therefore,  non-responders  to  a  previous  PegIFN  and  RBV
therapy  will  unlikely  respond  to  the  same  treatment  and
therefore  the  correct  strategy  involves  using  more  efﬁ-
cient  drugs.  When  double  therapy  is  the  single  option,
non-responder  genotype  1  patients  should  be  maintained  on
treatment  for  at  least  48  weeks  if  HCV  RNA  is  undetectable
at  week  12.  A  global  56%  SVR  has  been  found  in  this  context.
In  non-genotype  1  patients  with  an  urgent  need  for  retreat-
ment,  double  therapy  should  be  extended  over  48  weeks
in  patients  with  genotype  2  and  3  and  up  to  72  weeks  in
patients  with  genotype  4.14
2.3.  Factors  related  to  treatment  response
Double  therapy  SVR  is  inﬂuenced  by  demographic,  genetic,
metabolic  and  viral  factors.  Younger  age,18,21 female
gender,22 absence  of  visceral  obesity,  insulin  resistance  and
diabetes,23--25 mild  liver  ﬁbrosis,18,26 IL28B  polymorphism
CC,27 viraemia  <  400,000  IU/mL28 and  RVR29 are  favourable
response  indicators.  According  to  the  existing  number
of  factors,  therapy  success  in  patients  with  genotype  1
may  vary  between  27%  and  100%.30 An  estimated  SVR
rate  above  80%  with  double  therapy  makes  it  compet-
itive  with  ﬁrst-generation  protease  inhibitors,  when  the
patient  with  a  genotype  IL28B  polymorphism  CC  or  HCV
RNA  <  400,000  IU/mL  achieves  RVR.30 In  non-cirrhotic  naïve
patients,  with  <600,000  IU/mL  viraemia  and  RVR,  the  addi-
tion  of  a  protease  inhibitor  does  not  seem  to  add  any
therapeutic  beneﬁt.31
A  simple  score  combining  some  of  the  routine  basal
parameters  for  the  assessment  of  patients  who  underwent
treatment,  such  as  age,  body  mass  index,  platelet  count,
ALT,  AST  and  HCV  RNA,  allows  for  the  identiﬁcation  of  Cau-
casian  patients  with  genotype  1  likely  to  achieve  SVR  with
double  therapy.21 In  this  score,  patients  with  a  coefﬁcient
≥5  achieved  a  77%  SVR,  which  increased  to  87%  if  RVR  was
achieved.21 Nevertheless,  the  percentage  of  patients  with
favourable  conditions  for  a  response  above  80%  does  not
exceed  20%.21,30 The  same  applies  to  IL28B  CC,  present  in
only  one  quarter  of  the  patients  with  genotype  1 and  to  RVR,
which  is  achieved  by  only  16%  of  the  same  patients.29
3. Triple therapy with 1 st generation
protease  inhibitors
Since  2011,  the  association  of  pegylated  interferon  plus
ribavirin  with  a  NS3/4a  protease  inhibitor  (PI),  boceprevir
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BOC)  or  telaprevir  (TVR),  became  the  standard  treatment
or  patients  with  Hepatitis  C  infected  with  genotype  1.
.1.  Therapeutic  regimen
aïve  patients:
I.  Boceprevir:  800  mg  (4  tablets)  t.i.d.,  taken  with  meals,
plus  PegIFN/RBV,  for  24  to  48  weeks.  It  includes  a  prior
lead-in  period  (4  weeks  of  pegylated  interferon  plus  rib-
avirin).  This  aims  to  reduce  HCV  RNA  levels,  in  order
to  reduce  the  risk  of  virological  escape  or  resistance,  to
assess  sensitivity  towards  interferon  and  to  estimate  the
chance  of  SVR.
• A  28-week  treatment  should  be  considered  for  non-
cirrhotic  patients  in  whom  HCV  RNA  is  undetectable
at  week  8  and  24.
• Treatment  should  be  discontinued  with  HCV  RNA
above  100  IU/mL  at  week  12  or  detectable  at  week
24.
II.  Telaprevir:  750  mg  (3  tablets)  b.i.d.,  with  a  high-fat
meal,  plus  PegIFN/RBV,  for  3  months,  followed  by  double
therapy  over  another  12--36  weeks.
•  A  24-week  treatment  should  be  considered  in  non-
cirrhotic  telaprevir/PegIFN/RBV-  treated  patients,
with  undetectable  HCV  RNA  at  week  4  and  12.
II.  Boceprevir  or  telaprevir-treated  cirrhotic  patients
should  undergo  a  48-week  treatment.
Non-responders:
I.  The  therapy  regimen  is  similar  to  the  naïve  patient’s
regimen.  Boceprevir-retreated  patients  with  HCV
RNA  >  100  IU/mL  at  week  12  should  discontinue  treat-
ment,  in  order  to  avoid  emerging  viral  resistance.
Telaprevir-retreated  patients  with  HCV  RNA  >  1000  IU/mL
at  week  4 or  12  should  also  discontinue  therapy.
I.  Non-responder’s  treatment  should  include  a  lead-in
stage.  In  the  event  of  a  HCV  RNA  reduction  ≥1  log10
at  week  4,  boceprevir  or  telaprevir  treatment  should  be
continued  according  to  the  standard  regimen.
Due  to  the  predicted  absence  of  response  or  to  the  risk
f  viral  resistance,  patients  with  no  virological  response  or
elapsers  with  one  of  the  PI,  should  not  be  retreated  with
nother  inhibitor.
Triple  therapy  is  associated  with  a  higher  number  of
dverse  effects.  In  boceprevir  clinical  trials,  anaemia  and
ysgeusia  were  the  most  common  secondary  effects,  while
n  telaprevir  clinical  trials  these  included  anaemia,  rash,
norectal  symptoms  and  pruritus.
Haemoglobin  levels  <  10  g/dL  occurred  in  49%  and  36%  of
oceprevir  and  telaprevir-treated  patients,  respectively.
Monitoring  of  adverse  effects  should  be  particularly  care-
ul  in  patients  with  compensated  liver  cirrhosis,  especially
or  haematological  disorders,  which  are  the  most  com-
on.  The  CUPIC  study32 showed  that  cirrhotic  patients
ith  platelet  count  ≤100,000  mm--3 and  albumin  concen-
ration  <35  gr/L  are  more  prone  to  development  of  serious
omplications,  occurring  in  44%  of  the  patients  and  as  such
hose  patients  should  not  undergo  the  triple  therapy.
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.2.  Efﬁcacy
n  registry  studies,  SVR  varied  according  to  patient’s  prior
herapy:  naïve  or  previously  treated  patients.  In  naïve
atients,  the  SVR  increase  regarding  patients  treated
ith  PegIFN/RBV  combination  was  28%  and  31%  with  BOC
nd  TVR,  respectively.6,7 In  non-responders,  the  SVR  rate
ncrease  with  BOC  reached  45%  globally:  46%  increase  in
elapsers  and  45%  in  partial  responders.33 In  TVR-retreated
atients,  global  SVR  rate  was  49%:  64%  increase  in  relapsers,
9%  in  partial  responders  and  28%  in  null  responders.34 In
hort,  triple  therapy  is  particularly  useful  in  non-responders
o  a  previous  PegIFN/RBV  treatment,  mainly  in  relapsers
nd,  to  a  lesser  extent,  in  partial  responders  and  null
esponders.33,34
The  ILUMMINATE  study35 showed  that,  in  naïve  patients,
he  12-week  triple  therapy  regimen  with  TVR,  followed  by
2  additional  weeks  of  PegIFN/RBV  treatment,  was  as  effec-
ive  as  a  36-week  regimen  with  PegIFN/RBV,  as  long  as
RVR  (extended  rapid  virological  response)  occurred  (unde-
ectable  HCV  RNA  at  week  4  and  12).  Boceprevir  treatment
uration  may  also  be  guided  by  virological  response  and
hould  be  reduced  to  28  weeks  in  naïve  patients  with  unde-
ectable  HCV  RNA  at  week  8  and  24.  Patients  with  HCV  RNA
till  detectable  at  week  8  and  24  should  keep  triple  ther-
py  until  week  36  and  PegIFN/RBV  therapy  until  week  48.14
VR,  occurring  in  58%  of  TVR-treated  patients  and  in  47%
f  BOC-treated  patients,  predicts  89%  and  96%  SVR  rate,
espectively.  Therefore,  in  non-cirrhotic  patients  with  RVR
herapy  may  be  reduced  to  24  weeks  with  TVR  and  28  weeks
ith  BOC.  In  cirrhotic  naïve  patients,  therapy  should  not  be
hortened  regardless  of  the  viral  kinetics.
In  patients  with  advanced  liver  ﬁbrosis  (F3--F4),  the  SVR
ates  are  generally  higher  in  BOC  or  TVR  therapy,  when  com-
ared  with  the  rates  obtained  in  double  therapy-treated
atients,  mainly  in  patients  with  RVR.6,7
Treatment  should  be  discontinued,  due  to  its  inefﬁcacy,
n  triple  therapy  with  BOC,  when  HCV  RNA  is  >100  IU/mL  at
eek  12  or  when  detectable  at  week  24.  Likewise,  with  TVR,
hen  HCV  RNA  is  >1000  IU/mL  at  week  4  or  12.
.3.  Factors  related  to  treatment  responses  for  double  therapy,  we  may  also  estimate  which  patients
ill  likely  achieve  SVR  with  triple  therapy  (Table  1).  SPRINT
6 and  REALIZE34 studies  showed  that  genotype  IL28B  CC  is
 strong  SVR  predictive  factor,  allowing  for  the  shortening
Table  1  Negative  predictive  factors  of  sustained  virologi-
cal response  (SVR)  in  chronic  Hepatitis  C  genotype  1  patients.
•  Baseline  HCV  RNA  >800,000  IU/mL
• Advanced  liver  disease  and/or  liver  cirrhosis  (F3--F4)
• IL28B  CT/TT
• Non-responders  to  therapy  with  PegIFN/RBV
• Age  >  40
•  Black  ethnicity
• Body  mass  index  (BMI)  >  30
• Diabetes  mellitus
•  Genotype  1a
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f  treatment  duration.  Nevertheless,  the  T  allele  negative
redictive  value  is  not  powerful  enough  to  contra-indicate
herapy,  as  SVR  may  be  achieved,  particularly  in  patients
ith  RVR.  HCV  RNA  undetectability  at  week  4  (RVR)  showed
o  be  as  powerful  or  an  even  more  powerful  SVR  predictive
actor  than  the  presence  of  genotype  CC.  In  boceprevir-
reated  patients,  a  >1  log10 decrease  in  HCV  RNA  at  week  4
lead-in  stage  with  PegIFN/RBV)  showed  to  be  a  stronger  SVR
ndicator  than  IL28B.36 SVR  rate  in  these  patients  was  nine
imes  higher  than  SVR  for  patients  with  <1  log10 decrease.36
n  addition,  an  undetectable  HCV  RNA  at  week  8  (fourth
eek  of  triple  therapy)  increases  to  96%  the  SVR  rate.36
ow  basal  viraemia,  absence  of  cirrhosis  and  BMI  (body  mass
ndex)  ≤30  are  also  independent  SVR  factors.36 In  patients
ith  advanced  liver  ﬁbrosis  (F3--F4),  triple  therapy  showed
o  be  more  efﬁcient  than  double  therapy,  not  only  in  naïve
atients,  but  also  in  non-responders.37 Response  to  inter-
eron  in  the  lead-in  stage,  as  well  as  undetectable  HCV  RNA
t  week  8,  worked  as  SVR  predictors  in  these  patients.37
evertheless,  we  should  remark  that  the  major  factor  of
esponse  to  triple  therapy  in  non-responders  is  the  type
f  response  to  double  therapy,  since  relapsers,  regardless
f  the  ﬁbrosis  stage,  achieve  SVR  rates  consistently  above
0%.38
BOC  and  TVR-treated  patients  are  commonly  treated  with
ther  medication  and,  since  these  may  inhibit  liver  enzymes,
uch  as  P450  cytochrome,  they  may  potentially  induce  drug
nteractions.  It  is  therefore  important  to  be  aware  of  drug
nteractions  and  to  inform  patients  about  this  risk.39
. Triple therapy with sofosbuvir or
imeprevir
he  sofosbuvir  plus  PegIFN/RBV  combination  is  currently
ne  of  the  most  efﬁcient  associations  for  reaching  cure  of
epatitis  C  infection.  Sofosbuvir  is  a  powerful  nucleotide
olymerase  inhibitor  with  pangenotypic  action.40,41 It  has
 predominant  renal  excretion  and  does  not  require
ose  adjustment  when  the  creatinine  clearance  is  above
0  mL/min.
Simeprevir,  a 2nd  generation  NS3/NS4A  protease
nhibitor,  one  thousand  times  more  powerful  than  the  1st
eneration  protease  inhibitors  (PIs),  is  recommended  for
reatment  of  patients  with  genotype  1  and  genotype  4,  in  a
aily  dose  of  150  mg.42 It  must  be  taken  with  meals  (fatty  or
ot),  it  undergoes  liver  metabolism  through  CYP3A4  and  has
 renal  excretion  below  1%.  Although  less  frequently  than
he  1st  generation  PIs,  it  may  also  interact  with  other  drugs
hat  are  enzyme  inhibitors  or  inducers.  Even  though  serum
oncentrations  increase  in  patients  with  liver  failure,  there
s  no  need  for  dose  adjustment  in  the  presence  of  light  to
oderate  hepatic  impairment.43
.1.  Naïve  patients
.1.1.  Sofosbuvir
herapeutic  regimen.  In  patients  with  genotype  1,  4,  5  and
,  sofosbuvir  is  recommended  in  a  single  daily  dose  of  400  mg
ssociated  to  peginterferon  alfa-2a  and  ribavirin  in  standard
oses.  Triple  therapy  must  be  followed  for  12  weeks.14
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In  patients  with  genotype  3,  when  triple  therapy  is  the
option,  sofosbuvir  must  be  administered  in  a  400  mg  single
daily  dose  associated  to  peginterferon  alfa  and  ribavirin  in
the  standard  doses  for  12  weeks.
Efﬁcacy.  Global  SVR  was  91%  in  the  NEUTRINO  trial10:  90%
in  genotype  1,  96%  in  genotype  4  and  100%  in  genotype  5  and
6.  In  cirrhotic  patients,  SVR  was  80%.  SVR  was  slightly  higher
in  patients  with  IL28B  CC  (98%  vs.  87%),  low  viraemia  (97%)
and  genotype  1a  (92%)  vs.  1b  (82%).  Sofosbuvir  was  well  tol-
erated  and  allowed  for  a  SVR  improvement  of  approximately
30%  vs.  the  PegIFN/RBV  group  (58%).  The  efﬁcacy  in  geno-
type  4,  5  and  6 was  very  favourable  although  difﬁcult  to
analyze  given  the  reduced  number  of  patients  included.
4.1.2.  Simeprevir
Therapeutic  regimen.  Simeprevir  is  recommended  for
patients  with  genotype  1  and  4,  including  those  patients  with
liver  cirrhosis.  The  daily  dose  is  150  mg  in  association  with
PegIFN/RBV  for  12  weeks,  followed  by  12  or  36  weeks  of
PegIFN/RBV.44,45 In  patients  reaching  HCV  RNA  <  25  IU/mL  at
week  4  and  undetectable  at  week  24  (85%  in  QUEST-1  trial
and  91%  in  QUEST-2  trial),  treatment  should  be  discontin-
ued  at  week  24,  while  in  the  remaining  patients  it  should
be  extended  until  week  48.  Simeprevir  should  be  discon-
tinued  if  HCV  RNA  level  is  >1000  IU/mL  at  week  4,  keeping
PegIFN/RBV.  This  regimen  is  not  recommended  for  patients
with  genotype  1a  and  a  NS3  protease  Q80K  polymorphism.
Efﬁcacy.  The  efﬁcacy  of  simeprevir,  peginterferon  and
ribavirin  combination  has  been  assessed  in  QUEST-1  and
QUEST-2  trials.44,45 SVR12  (sustained  virological  response  12
weeks  after  completion  of  HCV  treatment)  was  80%  and  81%
in  QUEST-1  and  QUEST-2  trials  (European  patients),  respec-
tively.  In  the  same  studies,  RVR  was  achieved  in  80%  and
79%  vs.  12%  and  13%  in  the  PegIFN/RBV  group.  In  QUEST-1
as  in  QUEST-2  trials,  most  patients,  85%  and  86%  respec-
tively,  underwent  a  24-week  treatment  only,  as  they  met
the  Response-Guided  Therapy  (RGT)  criteria.  From  these,
91%  and  86%,  in  QUEST-1  and  QUEST-2  trials,  respectively,
achieved  SVR-12.  In  each  of  these  studies,  the  patients
with  genotype  1a  with  a  Q80K  polymorphism  obtained  lower
SVR-12  rates  than  patients  with  genotype  1a  without  such
polymorphism  and  with  genotype  1b.  SVR12  was  signiﬁcantly
higher  in  every  stage  of  liver  ﬁbrosis,  including  cirrho-
sis.  Simeprevir  is  well  tolerated,  without  any  differences
in  adverse  effects  incidence  between  simeprevir-treated
patients  and  patients  treated  with  PegIFN/RBV  alone.44,45
4.2.  Non-responders
4.2.1.  Sofosbuvir
Therapeutic  regimen.  There  are  no  randomized  clinical
trials  in  this  group  of  patients  and  therefore  optimal  treat-
ment  duration  has  not  been  determined.  Nevertheless,  the
drug  SPC  (Summary  of  Product  Characteristics)  considers
the  possibility  of  extending  triple  therapy  with  sofosbuvir
in  the  standard  doses  up  to  24  weeks,  especially  in  more
difﬁcult-to-treat  patients:  liver  cirrhosis,  advanced  age,
black  ethnicity,  metabolic  syndrome,  IL28B  non-CC  or  high
basal  viraemia.  In  these  patients,  extrapolation  of  known
data  from  double  therapy  we  anticipate  lower  SVR  rates.
s
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In  patients  with  genotype  3  non-responders  to  previous
herapy,  sofosbuvir  triple  combination  for  12  weeks,  in  a
aily  dose  of  400  mg  associated  to  PegIFN/RBV,  is  an  alter-
ative  to  interferon-free  double  therapy  for  24  weeks  with
ofosbuvir  and  ribavirin.14
Efﬁcacy.  In  the  LONESTAR-2  II-b  stage  trial,12 sofosbu-
ir,  peginterferon  and  ribavirin  combination  efﬁcacy  was
ssessed  in  patients  with  genotype  2  and  3  non-responders
r  relapsers  to  previous  treatment  with  PegIFN/RBV,  from
hich  55%  were  cirrhotic.  SVR12  was  96%  in  patients  with
enotype  2  (with  liver  cirrhosis:  93%,  non-cirrhotic:  100%)
nd  83%  in  patients  with  genotype  3  (with  or  without
irrhosis).
.2.2.  Simeprevir
herapeutic  regimen.  No  simeprevir  phase  III  study  has  been
ublished  in  non-responders.  According  to  EASL  (European
ssociation  for  the  Study  of  the  Liver)  guidelines,14 simepre-
ir  should  be  used  in  a daily  dose  of  150  mg  in  association
ith  peginterferon  and  ribavirin,  for  12  weeks,  in  non-
esponder  genotype  1  patients,  followed  by  12  additional
eeks  of  peginterferon  and  ribavirin  for  relapsers  and  36
dditional  weeks  (total  duration  of  48  weeks)  for  partial  and
ull  responders,  including  cirrhotic  patients.
Efﬁcacy.  In  the  ASPIRE  trial,46 SVR24  was  higher  in  the
roups  treated  with  150  mg/day  of  simeprevir  for  12  weeks
patients  with  24  and  48  weeks  of  treatment  were  grouped),
n  comparison  with  PegIFN/RBV  group:  relapsers  89%  vs.
7%,  partial  responders  86%  vs.  9%,  null  responders  59%
s.  19%.  The  IL28B  polymorphism  was  not  a  SVR  predic-
or.  In  difﬁcult-to-treat  patients  (F3  and  F4),  the  virological
esponse  was  higher  in  all  groups  treated  with  simeprevir.
VR24  in  cirrhotic  patients  was  77%  in  relapsers,  44%  in  par-
ial  responders  and  28%  in  null  responders.  In  the  PROMISE
hase  III  study47 that  included  genotype  1  patients  who
elapsed,  simeprevir  regimen’s  efﬁcacy  was  79.2%  vs.  36.1%
n  the  PegIFN/RBV  group.
Safety  proﬁle.  Sofosbuvir  has  an  excellent  safety  proﬁle.
o  patient  developed  any  resistance  or  presented  viral  reac-
ivation  during  treatment.  Sofosbuvir  was  well  tolerated,
ithout  any  additional  adverse  effects  beyond  those  asso-
iated  to  interferon  and  ribavirin.  The  most  frequent  were
nsomnia,  fatigue,  nausea  and  headache.  It  is  nevertheless
ecommended  that  sofosbuvir  should  not  be  used  alone  in
he  treatment  of  Hepatitis  C  and  should  be  discontinued
henever  the  associated  antiviral  drug  is  discontinued.  The
ose  of  sofosbuvir  should  never  be  modiﬁed,  even  in  elderly
atients.  As  its  liver  metabolism  does  not  require  CYP3A4,
he  risk  of  drug  interactions  is  smaller.  In  addition,  there
s  no  interaction  with  calcineurin  inhibitors  but  when  asso-
iated  to  cyclosporine  a  slight  increase  of  serum  level  was
ocumented.40
The  most  frequent  adverse  effects  with  simeprevir  were
atigue,  rash  and  neutropenia.  The  incidence  of  severe
ash  (grade  3  or  4),  besides  being  rare,  was  not  signiﬁ-
antly  different  from  those  occurring  in  patients  treated
ith  peginterferon  and  ribavirin  alone.  Hyperbilirubinemia
as  more  common  in  the  ﬁrst  2  weeks  of  treatment  with
imeprevir,  but  was  not  associated  to  other  hepatic  abnor-
alities  nor  did  it  interfere  with  SVR.
Factors  related  to  treatment  response.  With  sofosbuvir,
aseline  and  on-treatment  factors  related  to  response  to
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Table  2  Beneﬁts  of  all-oral  therapy  in  chronic  Hepatitis  C.
•  Cure  rates  above  90%,  even  in  cirrhotic  patients
• Shortening  of  therapy  to  12  or  even  8  weeks,  including
traditionally  more  difﬁcult  genotypes
• Overcomes  the  problems  of  interferon  use  in  injection
drug users.  Adverse  reactions  prevent  its  use  in  many
neuropsychiatric,  immune  and  haematological  (anaemia,
leukopenia,  thrombocytopenia)  disorders
• Reduced  incidence  of  adverse  reactions
• Excellent  compliance  with  reduced  impact  on  quality  of
life
• In  most  cases,  ribavirin  is  not  necessary  (absence  of
anaemia,  mutagenic  disorders,  cough,  need  for  double
contraception,  etc.)
• Irrelevance  of  the  traditional  predictive  response  factors
(BMI, IL28B,  cirrhosis,  RVR,  genotype,  ethnicity,  etc.)
• Use  in  ineligible  patients  for  therapy  with  interferon:
decompensated  cirrhosis,  pre  and  post-liver  transplant,
thrombocytopenia,  depression,  anxiety,  severe  systemic
disease,  HCC  in  transplant  regimen,  advanced  age,  HIV
co-infection,  haemoglobinopathies,  concomitant  use  of
methadone  or  buprenorphine
•  Some  drugs  have  a  pangenotypic  effect
• Non-signiﬁcant  drug  interactions
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5.1.  Therapeutic  regimen• Without  absolute  contraindications
ouble  therapy  with  peginterferon  and  ribavirin  lost  their
mpact.  However,  in  patients  with  genotype  1,  IL28B  CC,  a
ow  basal  viraemia,  genotype  1b  and  the  absence  of  liver
irrhosis  remain  favourable  factors  of  response  to  triple
herapy.10
Therapy  may  be  shortened  to  24  weeks  using  simeprevir
nd  RGT  if  HCV  RNA  <  25  IU/mL  at  week  4  and  undetectable
CV  RNA  at  week  12  and  24.44,45 Therapy  should  be  dis-
ontinued  when  HCV  RNA  is  above  25  IU/mL  at  week  4,  12
r  24.  Viral  reactivation  is  assumed  when  there  is  >1  log10
T
a
Table  3  Direct-acting  antiviral  agents  (DAAs)  approved  or  awai
Europe (EMA),  used  in  all-oral  interferon-free  combinations  of  dru
Class  Target  Ge
Protease  inhibitors:
Simeprevir  (SMV)  NS3/4A  1,  
Paritaprevira NS3/4A  1  
Asunaprevir (ASV)  NS3A  1  
Replication  complex  inhibitors:
Daclatasvir  (DCV)  NS5A  1,3
Ledipasvir (LDV)  NS5A  1,4
Ombitasvir NS5A  1  
Polimerase inhibitors:
Nucleotide  analogue:
Sofosbuvir  (SOF)  NS5B  Pan
Non nucleotide:
Dasabuvir  NS5B  1,4
a Co-formulated with ritonavir and ombitasvir.
b Co-formulated with sofosbuvir.J.  Velosa  et  al.
CV  RNA  increase  in  relation  with  the  lowest  obtained  value
r  when  HCV  RNA  is  >100  IU/mL  in  patients  previously  with
ndetectable  or  <  25  IU/mL  HCV  RNA  levels.42,43
. Interferon-free therapy
n  all-oral  therapy  will  be  the  new  paradigm  in  chronic
epatitis  C  therapy  in  the  near  future  (Table  2).  The
nterferon-free  therapy,  with  or  without  ribavirin,  is  more
fﬁcient,  shorter  and  better  tolerated  by  naïve48,49 and
reatment-experienced  patients.50,51 Oral  therapy  for  all
atients  will  be  a matter  of  time,  once  economic  constraints
hat  are  currently  conditioning  its  use  are  overcome.
The  EASL14 and  AASLD/IDSA  (American  Association  for
he  Study  of  Liver  Diseases/Infectious  Diseases  Society  of
merica)52 guidelines  already  include  all-oral  therapy  as  an
ption  for  almost  all  HCV  genotype,  including  naïve  and
on-responders  to  previous  therapy  with  peginterferon  and
ibavirin,  alone  or  in  combination  with  1st  generation  pro-
ease  inhibitors  and  in  cirrhotic  patients.
Some  doubts  remain  regarding  the  ideal  therapy  regimen
n  order  to  achieve  a  SVR  rate  above  the  desired  90%.  In  cir-
hotic  genotype  3  patients,  naïve  or  treatment-experienced,
t  is  not  yet  clear  whether  a 24-week  treatment  with
ofosbuvir  plus  ribavirin53 or  a  12-week  of  the  same  combina-
ion  associated  to  interferon  would  be  the  best  treatment.
n  addition,  in  cirrhotic  genotype  1a  null  responders,  the
xtension  of  treatment  for  another  24  weeks  improves  SVR
ate.54 We  should  also  remark  the  fact  that  there  are  some
aps  in  the  treatment  of  non-1  genotype  patients,  due  to
nsufﬁcient  research  with  some  of  the  new  direct-acting
ntiviral  agents  (DAAs).able  3  shows  oral  therapy  regimens  for  which  there  is
lready  agreement.  Ribavirin  may  be  associated  in  some
ting  approval  by  regulatory  authorities  in  the  USA  (FDA)  or
gs.
notype  Daily  dose/duration
4  1  caps  150  mg/day,  12  weeks
1  tablet  150  mg/day,  12  weeks
1  tablet  100  mg,  b.i.d.
,4?  1  tablet  60  mg/day,  12  weeks
?  1  tabletb 90  mg/day,  12  weeks
1  tablet  25  mg/day,  12  weeks
genotypic  1  tablet  400  mg/day,  12  weeks
?  1  tablet  250  mg,  b.i.d.,  12  weeks
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Table  4  Oral  therapy  regimens  and  sustained  virological  response  (SVR)  in  chronic  Hepatitis  C  infection.
Combination  Dose  Duration  SVR12a
Sofosbuvir/Ribavirin
Genotype  1
Naïve  400  mg/1.0--1.2  g  24  weeks  84%
Genotype 2
Naïve  400  mg/1.0--1.2  g 12  weeks 97%
Previously treated 400  mg/1.0--1.2  g 12  weeks 90%
Genotype 3
Naïve  400  mg/1.0--1.2  g  24  weeks  94%
Previously treated  400  mg/1.0--1.2  g  24  weeks  79%
Sofosbuvir/Ledipasvir
Genotype 1
Naïve  400  mg/90  mg  12  weeks  99%
Cirrhosis 400  mg/90  mg  12  weeks  97%
400 mg/90  mg  24  weeks  97%
Previously treated  400  mg/90  mg  12  weeks  94%
Relapsers 400  mg/90  mg  12  weeks  95%
Non-responders  400  mg/90  mg  12  weeks  92%
Cirrhosis 400  mg/90  mg  12  weeks  86%
400 mg/90  mg  24  weeks  100%
Sofosbuvir/Simeprevir
Genotype 1
Naïve  (F3--F4)  400  mg/150  mg  12  weeks  100%
Null responders  400  mg/150  mg  12  weeks  93%
Sofosbuvir/Daclatasvir
Genotype 1
Naïve  400  mg/60  mg  24  weeks  100%
Previously treatedb 400  mg/60  mg  24  weeks  100%
Genotype 2  or  3
Naïve  400  mg/60  mg  24  weeks  93%
Paritaprevir/r/Ombitasvir/Dasabuvir/Ribavirin  150  mg/100  mg/25  mg/250  mg/1.0--1.2  g
Genotype 1
Naïve  As  above  12  weeks  96%
Previously treated
Relapsers  As  above  12  weeks  95%
Partial responders  12  weeks  100%
Null responders  12  weeks  95%
Cirrhosis: As  above
Naïve 12  weeks  94%
24  weeks  95%
Relapsers 12  weeks  97%
24  weeks  100%
Partial responders 12  weeks  94%
24  weeks  100%
Null responders 12  weeks  87%
24  weeks  95%
tion 
ir or 
v
r
aa SVR-12 -- sustained virological response 12 weeks after comple
b Patients previously treated with protease inhibitors (boceprev
cases  to  DAAs  in  patients  with  less  favourable  response  indi-
cators,  mainly  if  cirrhotic.
In  genotype  1  non-responders  to  triple  therapy  with
peginterferon,  ribavirin  and  boceprevir  or  telaprevir,  a
24-week  sofosbuvir  and  daclatasvir  combination  has  been
shown  to  be  very  efﬁcient.13
In  naïve  patients  it  seems  possible  to  shorten
to  8  weeks  the  treatment  duration  with  sofosbu-
w
r
mof HCV treatment.
telaprevir).
ir/ledipasvir  combination,  without  compromising  SVR
ate.55
In  patients  with  genotype  2,  oral  recommended  ther-
py  is  the  combination  of  sofosbuvir  with  ribavirin  for  12
eeks.53 In  non-responders,  the  association  of  interferon  is
ecommended.
In  genotype  3,  two  oral  therapy  alternatives  are  recom-
ended:  24-week  sofosbuvir  plus  ribavirin  or  sofosbuvir  plus
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aclatasvir  for  12  or  24  weeks  in  naïve  and  non-responders,
espectively.13,53
In  genotype  4,  data  are  scarce,  although  it  is
ssumed  that  12-week  sofosbuvir/simeprevir  or  sofosbu-
ir/daclatasvir  combinations  are  efﬁcient.14
.2.  Efﬁcacy
able  4  shows  the  different  oral  therapy  regimens  already
pproved,  or  awaiting  approval  by  regulatory  authorities,  as
ell  as  their  efﬁcacy.  The  SVR  rate  is  generally  above  95%,
egardless  of  prior  treatment-experience  and  independently
f  response  to  previous  therapy  with  PegIFN/RBV.51,56,57 In
reatment-experienced  patients  with  cirrhosis,  the  rates  of
VR  with  sofosbuvir  and  ledipasvir  combination  were  88%
nd  100%  after  12  or  24  weeks  of  therapy,  respectively50;
ith  paritaprevir/ritonavir  plus  ombitasvir  plus  dasabuvir
ere  98%  and  97%,  respectively.54 In  the  COSMOS  study
sofosbuvir  and  simeprevir),  the  rates  of  SVR  remained  high
n  patients  with  cirrhosis  with  or  without  ribavirin,  duration
f  treatment  (12  or  24  weeks)  or  previous  therapy.57
Current  trend  is  towards  excluding  ribavirin  from  ther-
py  regimens,  despite  the  association  of  ribavirin  with  DAAs
nd  the  24-week  extension  of  therapy  slightly  increases  the
VR  rate  in  more  difﬁcult-to-treat  patients:  cirrhotic,  null
esponder  genotype  1a  or  genotype  3  patients.13,53,54,58
Shortening  of  treatment  duration  from  12  to  8  weeks
oes  not  seem  to  affect  the  efﬁcacy  of  sofosbuvir/ledipasvir
ombination  (94%  vs.  95%,  respectively),  in  non-cirrhotic
enotype  1  patients.55 Genotype  3  patients  had  lower  SVR
ates  with  oral  therapy  than  the  remaining  genotypes,
articularly  in  cirrhotic  patients.53 In  this  genotype,  cur-
ently  the  most  difﬁcult  to  treat,  peginterferon  association
ay  signiﬁcantly  improve  the  SVR  rate  and  shorten  treat-
ent  to  12  weeks.
Regarding  patients  with  genotype  4,  data  are  scarce,  not
llowing  for  an  accurate  determination  of  which  is  the  best
lternative  oral  therapy.14
The  selection  of  simeprevir  (Q80K)  and  daclatasvir-
esistant  strains  (NS5A-A30K)  seems  to  only  occur  very
arely,  when  sofosbuvir  is  included  in  therapy  regimens.
1
a
a
Table  5  Therapeutic  strategy  in  chronic  Hepatitis  C  in  a  situatio
Double  therapy  Triple  therapy  
Baseline:
•  Genotype  2  and  3
• IL28B  CC
• HCV  RNA  <  400,000  IU/mL
• F0--F2
•  Young,  female,  BMI  ≤  22,
platelets  >  150  ×  103/dL,
ALT  >  3  ULN
Baseline:
•  Genotype  1b
• IL28B  CT/TT
• Compensated
(platelets  >  100
albumin  >  3.5  g/
•  Relapsers
• Black  ethnicit
diabetes  mellit
On treatment:
• RVR
•  >1  log10 decline  in  HCV  RNA
levels  at  week  4
On  treatment:
•  RVR
RVR, rapid virological response.J.  Velosa  et  al.
.3.  Factors  related  to  response  to  treatment
he  previously  described  factors  inﬂuencing  the  response  to
he  treatment  with  PegIFN/RBV  become  almost  meaningless
ith  the  combination  of  DAAs.  As  described,  only  genotype
a,  genotype  3  and  mainly  liver  cirrhosis  may  show  slight
eductions  in  SVR  rate.  These  are  susceptible  to  be  overcome
y  more  extensive  therapy  regimens.
. Therapeutic strategy
n  this  time  of  transition  towards  all-oral  therapies,  the
uidelines  for  treatment  of  Hepatitis  C  that  we  present
re  close  to  the  EASL  proposal.14 The  choice  of  therapeu-
ic  regimen  should  be  based  on  clinical  data  and  should
im  to  maximize  cure,  treating  the  highest  possible  number
f  patients,  according  to  budget  and  established  priorities
Table  5).  Patient’s  clinical  proﬁle,  previous  therapy  and  the
tage  of  liver  ﬁbrosis  will  lead  the  decision.
In  patients  with  genotype  1,  double  therapy  may  be  a
herapeutic  alternative  in  about  18%  of  the  patients  pre-
enting  a  set  of  good  SVR  indicators:  IL28B  CC,  F0-2,  HCV
NA  <  400.000  IU/mL  and/or  RVR.  In  countries  with  high  bud-
et  restrictions,  triple  therapy  with  ﬁrst  generation  protease
nhibitors,  boceprevir  or  telaprevir,  could  be  an  affordable
lternative.  However,  a  response  guided  triple  therapy  with
imeprevir  in  patients  with  genotype  1b  and  genotype  1a
ithout  Q80K  polymorphism,  naïve  or  relapsers,  is  a  bet-
er  alternative  with  an  expected  80%  SVR  efﬁcacy.  Patients
ith  interferon  intolerance  or  contraindications  to  its  use
nd  in  non-responder  cirrhotic  patients,  the  preferential
ption  should  be  all-oral  therapy  with  sofosbuvir  associated
o  simeprevir  or  daclatasvir.
In patients  with  genotype  2,  either  double  therapy  or  the
ssociation  with  sofosbuvir  in  cirrhotic  or  non-responders
s  recommended.  In  patients  intolerant  to  interferon,  a
2-week  course  of  sofosbuvir  with  ribavirin  obtains  equiv-
lent  results  in  naïve  patients.
In  non-cirrhotic  patients  with  genotype  3,  double  ther-
py  is  recommended  or,  in  patients  ineligible  for  interferon,
n  of  limited  economic  resources.
All-oral  therapy
 cirrhosis
 ×  103/dL,
dL)
y,  BMI  >  22,
us
Baseline:
•  Genotype  1,  2,  3,  4,  5,  6
• Genotype  1a
• Cirrhosis
• Liver  transplantation
• Partial  and  null  responders
• Non-responders  to  triple
therapy
• Ineligible  for  interferon
•  Ineligible  for  ribavirin
11
1
1
1
1
1
1
2
2
2
2
2
2
2Guide  for  antiviral  therapy  of  Hepatitis  C  
a  12-week  combination  of  sofosbuvir  with  ribavirin.  In
cirrhotic  non-responders,  with  intolerance  or  contraindi-
cation  to  interferon,  the  best  option  would  be  the
sofosbuvir/daclatasvir  combination.  In  non-cirrhotic  non-
responders,  the  most  reasonable  option  would  be  to  wait
for  more  cost-effective  therapies.
In  patients  with  genotype  4,  there  are  no  well-
documented  alternatives  to  double  therapy.  EASL  rec-
ommends  12-week  sofosbuvir,  peginterferon  and  ribavirin
regimen  or,  in  the  case  of  patients  intolerant  to  interferon,
a  12-week  course  of  sofosbuvir  associated  to  simeprevir  or
daclatasvir.
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